Shanghai Pharmaceuticals Holding Co.,Ltd.

Lumosa Therapeutics' LT3001 Shows Promise in Phase II Acute Ischemic Stroke Trial

- Lumosa Therapeutics' LT3001 demonstrated a robust safety profile and tolerability in a Phase II clinical trial for acute ischemic stroke patients. - The trial, conducted by Shanghai Pharma, showed comparable adverse event rates between LT3001 and placebo groups over 90 days. - Preliminary efficacy data indicated a promising proportion of patients achieving favorable outcomes on the modified Rankin Scale (mRS) at Day 90 post-treatment. - Lumosa plans to collaborate with Shanghai Pharma and seek international licensing to advance LT3001's global development for stroke treatment.